VasoDynamics establishes Clinical and Scientific Advisory Board

Leading cancer research and treatment experts join our journey to tackle the debilitating side effects of cancer therapies

30th July 2022 – VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, today announces that it has established a Clinical & Scientific Advisory Board to support the preclinical and clinical development of our innovative, topical programmes for the prevention of mucositis, dermatitis and alopecia (hair loss) induced by chemotherapy and radiotherapy.

The appointments include:
• Dr Barry Quinn, Clinical Adviser, Senior Lecturer, Queen’s University, Belfast
• Dr Rafael Moleron, Medical Adviser, Consultant Clinical Oncologist, Aberdeen Royal Infirmary
• Prof. Kairbaan Hodivala-Dilke, Scientific Adviser, Deputy Institute Director, Professor of the Tumour Microenvironment at Barts Cancer Institute
• Prof. Dr Shah-Jalal Sarker, Biostatistics Adviser, Honorary Associate Professor, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences

Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:

“We are delighted to have attracted a team of highly experienced specialists to support the further development of our programmes, and enhance our engagement with academia, leading clinical centres, medical charities and patient groups.”

For enquiries, please contact:

Dr Ningfeng Fiona Li, CEO +44 7969132263
fiona.li@vasodynamics.co.uk
Gary Bower, COO +44 7960388412
gary.bower@vasodynamics.co.uk

Notes to Editors:

About VasoDynamics

VasoDynamics is a UK-based pharmaceutical development company focused on improving the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, VasoDynamics is developing cost-effective medicines for the prevention and treatment of debilitating, and often dose-limitin,g complications of cancer therapy, such as chemotherapy and radiotherapy-induced mucositis, dermatitis and hair-loss. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculature to achieve selective protection of normal tissue during cancer treatment whilst facilitating anti-cancer therapy efficacy.